The Cambridge biotech turned messenger RNA from a lab curiosity into a platform for printing medicines from genetic code - vaccines, cancer shots, and rare-disease drugs that share one factory and swap out the instructions.
Flagship Pioneering is a Cambridge, Massachusetts life-sciences enterprise that invents, builds, and funds companies rather than merely investing in them. Founded in 1999 by Noubar Afeyan, the firm runs a systematic 'venture creation' engine - generating scientific hypotheses in-house, prototyping them in its own labs, and spinning validated concepts into independent operating companies in human health and sustainability. Its portfolio has produced more than 100 ventures, including Moderna, and it directs roughly $14 billion in capital.